Synthetic triterpenoids enhance transforming growth factor β/Smad signaling

Cancer Research

Volumn 63, Issue 6, 2003, Pages 1371-1376

  Suh, Nanjoo ^a   Roberts, Anita B ^b   Reffey, Stephanie Birkey ^b   Miyazono, Kohei ^c   Itoh, Susumu ^d   Ten Dijke, Peter ^d   Heiss, Elke H ^a   Place, Andrew E ^a   Risingsong, Renee ^a   Williams, Charlotte R ^a   Honda, Tadashi ^a   Gribble, Gordon W ^a   Sporn, Michael B ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CANCER INSTITUTE   (Japan)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OYL)IMIDAZOLE; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; ACTIVIN; BONE MORPHOGENETIC PROTEIN; CAGA PROTEIN; LUCIFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; PROTEIN CBP; PROTEIN P300; RECEPTOR SUBTYPE; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRITERPENOID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASSAY; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GENETIC TRANSFECTION; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETYLTRANSFERASES; ANIMALS; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; DRUG SYNERGISM; HISTONE ACETYLTRANSFERASES; IMIDAZOLES; LEUKEMIA, PROMYELOCYTIC, ACUTE; LUNG; MACROPHAGES; MICE; MINK; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OLEANOLIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS (GENETICS); RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD7 PROTEIN; TERPENES; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRITERPENES;

EID: 0037444161     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Fiocchi, C. TGF-β/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J. Clin. Investig., 108: 523-526, 2001.
2. Derynck, R., Akhurst, R. J., and Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet., 29: 117-129, 2001.
3. Nakao, A., Okumura, K., and Ogawa, H. Smad7: a new key player in TGF-β-associated disease. Trends Mol. Med., 8: 361-363, 2002.
4. Wakefield, L. M., and Roberts, A. B. TGF-β signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev., 12: 22-29, 2002.
5. Sporn, M. B., and Suh, N. Chemoprevention: an essential approach to controlling cancer. Nat. Rev. Cancer, 2: 537-543, 2002.
6. ten Dijke, P., Goumans, M. J., Itoh, F., and Itoh, S. Regulation of cell proliferation by Smad proteins. J. Cell. Physiol., 191: 1-16, 2002.
7. Massagué, J., and Wotton, D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J., 19: 1745-1754, 2000.
8. Miyazono, K., Kusanagi, K., and Inoue, H. Divergence and convergence of TGF-β/BMP signaling. J. Cell. Physiol., 187: 265-276, 2001.
9. Suh, N., Wang, Y., Honda, T., Gribble, G. W., Dmitrovsky, E., Hickey, W. F., Maue, R. A., Place, A. E., Porter, D. M., Spinella, M. J., Williams, C. R., Wu, G., Dannenberg, A. J., Flanders, K. C., Letterio, J. J., Mangelsdorf, D. J., Nguyen, L., Porter, W. W., Ren, R. F., Roberts, A. B., Roche, N. S., Subbaramaiah, K., and Sporn, M. B. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), with potent differentiating, anti-proliferative, and anti-inflammatory activity. Cancer Res., 59: 336-341, 1999.
10. Suh, N., Honda, T., Finlay, H. J., Barchowsky, A., Williams, C., Benoit, N. E., Xie, Q. W., Nathan, C., Gribble, G. W., and Sporn, M. B. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer. Res., 58. 717-723, 1998.
11. Honda, T., Rounds, B. V.,. Bore, L., Finlay, H. J., Favaloro, F. G., Jr., Suh, N., Wang,. Y., Sporn, M. B., and Gribble, G. W. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem., 43: 4233-4246, 2000.
12. Honda, T., Honda, Y., Favaloro, F. G., Jr., Gribble, G. W., Suh. N., Place, A. E., Rendi, M. H., and Sporn, M. B. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(1,1)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg. Med. Chem. Lett., 12: 1027-1030, 2002.
13. Konopleva, M., Tsao, T., Ruvolo, P., Stiouf, I., Estrov, Z., Leysath, C., Zhao, S., Harris, D., Chang, S., Jackson, E., Munsell, M., Suh, N., Gribble, G. W., Honda, T., May, W. S., Sporn M. B., and Andreeff, M. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood, 99: 326-335, 2002.
14. Wang, Y., Porter, W. W., Suh, N. Honda, T., Gribble, G. W., Leesnitzer, L. M., Plunket, K. D., Mangelsdorf, D. J., Blanchard, S. G., Willson, T. W., and Sporn, M. B. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO). is a ligand for the peroxisome proliferator-activated receptor-γ. Mol. Endocrinol., 14: 1550-1556, 2000.
15. Keski-Oja, J., Raghow, R., Sawdey, M., Loskutoff, D. J., Postlethwaite, A. E., Kang, A. H., and Moses, H. L. Regulation of mRNAs for type I plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-β. Divergent responses in lung fibroblasts and carcinoma cells. J. Biol. Chem., 263: 3111-3115, 1988.
16. Bae, H. W., Geiser, A. G., Kim, D. H., Chung, M. T., Burmester, J. K., Sporn, M. B., Roberts, A. B., and Kim, S. J. Characterization of the promoter region of the human transforming growth factor-β type II receptor gene. J. Biol. Chem., 270: 29460-29468, 1995.
17. Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., and Gauthier, J. M. Direct binding of Smad3 and Smad4 to critical TGF-β-inducible elements in the promoter of human plasminogen activator inhibitor-type I1gene. EMBO J., 17: 3091-3100, 1998.
18. Kawabata, M., Imamura, T., and Miyazono, K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev., 9: 49-61, 1998.
19. Shen, X., Hu, P. P., Liberati, N. T., Datto, M. B., Frederick. J. P., and Wang, X. F. TGF-β-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. Mol. Biol. Cell, 9: 3309-3319, 1998.
20. Feng, X-H., Zhang, Y., Wu, R-Y., and Derynck, R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for Smad3 in TGF-β-induced transcriptional activation. Genes Dev., 12: 2153-2163, 1998.
21. Janknecht. R., Wells, N. J., and Hunter, T. TGF-β-stimulated cooperation of Smad proteins with the coactivators CBP/p300. Genes Dev., 12: 2114-2119, 1998.
22. Itoh, S., Ericsson, J., Nishikawa, J., Heldin, C. H., and ten Dijke, P. The transcriptional co-activator P/CAF potentiates TGF-β/Smad signaling. Nucleic Acids Res., 28: 4291-4298, 2000.
23. Nakao, A., Imamura, T., Souchelnytskyi, S., Kawabata, M., Ishisaki, A., Oeda, E., Tamaki, K., Hanai, J., Heldin, C. H., Miyazono. K., and ten Dijke, P. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J., 16: 5353-5362, 1997.
24. Nakao, A., Afrakhte, M., Morén, A., Nakayama, T., Christian, J. L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N-E., Heldin, C-H., and ten Dijke, P. Identification of Smad7, a TGF-β inducible antagonist of TGF-β signaling. Natura (Lond.), 389: 631-635, 1997.
25. Hanyu, A., Ishidou, Y., Ebisawa, T., Shimanuki, T., Imamura, T., and Miyazono, K. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-β signaling. J. Cell. Biol., 155: 1017-1027, 2001.
26. Korchynskyi, O., and ten Dijke, P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Idl promoter. J. Biol. Chem., 277: 4883-4891, 2002.
27. Abe, M., Harpel, J. G., Metz, C. N., Nunes, I., Loskutoff, D. J., and Rifkin, D. B. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem., 216: 276-284, 1994.
28. Vodovotz, Y. Control of nitric oxide production by transforming growth factor-β1: mechanistic insights and potential relevance to human disease. Nitric Oxide, 1: 3-17, 1997.
29. Song, C. Z., Siok, T. E., and Gelehrter, T. D. Smad4/DPC4 and Smad3 mediate transforming growth factor-β (TGF-β) signaling through direct binding to a novel TGF-β-responsive element in the human plasminogen activator inhibitor-1 promoter. J. Biol. Chem., 273: 29287-29290, 1998.
30. Macias-Silva, M., Abdollah, S., Hoodless, P. A., Pirone, R., Attisano, L., and Wrana, J. L. MADR2 is a substrate of the TGF-β receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell, 87: 1215-1224, 1996.
31. Zhang, Y., Feng, X., We, R., and Derynck, R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature (Lond.), 383: 168-172, 1996.
32. 467 is required for Smad2-Smad4 complex formation and signaling. J. Biol. Chem., 272: 27678-27685, 1997.
33. Lagna, G., Hata, A., Hemmati-Brivanlou, A., and Massague, J. Partnership between DPC4 and Smad proteins in TGF-β signaling pathways. Nature (Lond.), 383: 832-836, 1996.
34. Moustakas, A., and Heldin, C. H. From mono- to oligo-Smads: the heart of the matter in TGF-β signal transduction. Genes Dev., 16: 1867-1871, 2002.
35. Attisano, L., and Wrana, J. L. Signal transduction by the TGF-β superfamily. Science (Wash. DC), 296: 1646-1647, 2002.
36. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S. C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell, 85: 403-414, 1996.
37. Horvai, A. E., Xu, L., Korzus, E., Brard, G., Kalafus, D., Mullen, T. M., Rose, D. W., Rosenfeld, M. G., and Glass, C. K. Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc. Natl. Acad. Sci. USA, 94: 1074-1079, 1997.
38. Nagarajan, R. P., Chen, F., Li, W., Vig, E., Harrington, M. A., Nakshatri, H., and Chen, Y. Repression of transforming growth factor-β-mediated transcription by nuclear factor κB. Biochem. J., 348: 591-596, 2000.
39. Kim, R. H., Flanders, K. C., Birkey Reffey, S., Anderson, L. A., Duckett, C. S., Perkins, N. D., and Roberts, A. B. SNIPI inhibits NF-κB signaling by competing for its binding to the C/H1 domain of CBP/p300 transcriptional co-activators. J. Biol. Chem., 276: 46297-46304, 2001.
40. Masumi, A., Wang, I. M., Lefebvre, B., Yang, X. J., Nakatani, Y., and Ozato, K. The histone acetylase PCAF is a phorbol-ester-inducible coactivator of the IRF family that confers enhanced interferon responsiveness. Mol. Cell. Biol., 19: 1810-1820, 1999.
41. Stadheim, T. A., Suh, N., Ganju, N., Sporn, M. B., and Eastman, A. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J. Biol. Chem., 277: 16448-16455, 2002.
42. Kim, Y., Suh, N., Spom, M. B., and Reed, J. C. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem., 277: 22320-22329, 2002.
43. Ito, Y., Pandey, P., Place, A., Spom, M. B., Gribble, G. W., Honda, T., Kharbanda, S., and Kufe, D. The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ., 11: 261-267, 2000.
44. Hayashi, H., Abdollah, S., Qiu, Y., Cai, J., Xu, Y-Y., Grinnell, B. W., Richardson, M. A., Topper, J. N., Gimbrone, M. A., Jr., Wrana, J. L., and Falb, D. The MAD-related protein Smad7 associates with the TGF-β receptor and functions as an antagonist of TGF-β signaling. Cell, 89: 1165-1173, 1997.
45. Monteleone, G., Kumberova, A., Croft, N. M., McKenzie, C., Steer, H. W., and MacDonald, T. T. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J. Clin. Investig., 108: 601-609, 2001.
46. Ulloa, L., Doody, J., and Massague, J. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. Nature (Lond.), 397: 710-713, 1999.
47. Bitzer, M., von Gersdorff, G., Liang, D., Dominguez-Rosales, A., Beg, A. A., Rojkind, M., and Bottinger, E. P. A mechanism of suppression of TGF-β/Smad signaling by NF-κB/Re1A. Genes Dev., 14, 187-197, 2000.
48. Letterio, J. J., and Roberts, A. B. Regulation of immune responses by TGF-β. Annu. Rev. Immunol., 16: 137-161, 1998.
49. Chen, W., and Wahl, S. M. TGF-β: receptors, signaling pathways and autoimmunity. Curr. Dir. Autoimmun., 5: 62-91, 2002.
50. Miyazono, K. TGF-β signaling by Smad proteins. Cytokine Growth Factor Rev., 11: 15-22, 2000.
51. Kusanagi, K., Inoue, H., Ishidou, Y., Mishima, H. K., Kawabata, M., and Miyazono, K. Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol. Biol. Cell, 11: 555-565, 2000.
52. Wakefield, L., Kim, S. J., Glick, A., Winokur, T., Colletta, A., and Sporn, M. B. Regulation of transforming growth factor-β subtypes by members of the steroid hormone superfamily. J. Cell. Sci. (Suppl.), 13: 139-148, 1990.
53. Wager, R. E., and Assoian, R. K. A phorbol ester-regulated ribonuclease system controlling transforming growth factor β1 gene expression in hematopoietic cells. Mol. Cell. Biol., 10: 5983-5990, 1990.
54. Falk, L. A., De Benedetti, F., Lohrey, N., Birchenall-Roberts, M. C., Ellingsworth, L. W., Faltynek, C. R., and Ruscetti, F. W. Induction of transforming growth factor-β1 (TGF-β1), receptor expression and TGF-β1 protein production in retinoic acid-treated HL-60 cells: possible TGF-β1-mediated autocrine inhibition. Blood, 77: 1248-1255, 1991.
55. 3 enhances the expression of transforming growth factor-β1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res., 55: 1540-1546, 1995.
56. 3 and its analogs. J. Biol. Chem., 273: 7749-7756, 1998.
57. Yanagisawa, J., Yanagi, Y., Masuhiro, Y., Suzawa, M., Watanabe. M., Kashiwagi, K., Toriyabe, T., Kawabata, M., Miyazono, K., and Kato, S. Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science (Wash. DC), 283: 1317-1321, 1999.
58. Song, C. Z., Tian, X., and Gelehrter, T. D. Glucocorticoid receptor inhibits transforming growth factor-β signaling by directly targeting the transcriptional activation function of Smad3. Proc. Natl. Acad. Sci. USA, 96: 11776-11781, 1999.
59. Matsuda, T., Yamamoto, T., Muraguchi, A., and Saatcioglu, F. Cross-talk between transforming growth factor-β and estrogen receptor signaling through Smad3. J. Biol. Chem., 276: 42908-42914, 2001.
60. Chipuk, J. E., Cornelius, S. C., Pultz, N. J., Jorgensen, J. S., Bonham, M. J., Kim, S. J., and Danielpour, D. The androgen receptor represses transforming growth factor-β signaling through interaction with Smad3. J. Biol. Chem., 277: 1240-1248, 2002.
61. Kang, H. Y., Lin, H. K., Hu, Y. C., Yeh, S., Huang, K. E., and Chang, C. From transforming growth factor-β signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc. Natl. Acad. Sci. USA, 98: 3018 3023, 2001.
62. Fu, M., Zhang, J., Zhu, X., Myles, D. E., Willson, T. M., Liu, X., and Chen, Y. E. Peroxisome proliferator-activated receptor-γ inhibits transforming growth factor-β-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J. Biol. Chem., 276: 45888-45894, 2001.
63. Reiss, M. Transforming growth factor-β and cancer: a love-hate relationship? Oncol. Res., 9: 447-457, 1997.
64. Massagué, J., Blain, S. W., and Lo, R. S. TGF-β signaling in growth control, cancer, and heritable disorders. Cell, 103: 295-309, 2000.
65. De Caestecker, M. P., Piek, E., and Roberts, A. B. Role of transforming growth factor-β signaling in cancer. J. Natl. Cancer Inst. (Bethesda), 92: 1388-1402, 2000.
66. Wahl, S. M. Transforming growth factor-β: the good, the bad, and the ugly. J. Exp. Med., 180: 1587-1590, 1994.